News

The Certified Service Provider program comprises a select list of strategic organizations that pass a rigorous assessment to use Agilent’s microarray platform. The program combines the provider’s focused

Since 1999, Mr Bailey has held leadership positions of increasing responsibility at ImClone Systems. Most recently he led ImClone’s worldwide commercial organization, responsible for commercial aspects for the

This is said to be the first acquisition for Innovative Health Sciences (IHSI) since the name change from Royal Acquisitions and Development to Innovative Health Sciences. Concurrent with

The company has also announced that it has successfully petitioned the FDA to eliminate the need for pre-mixed solutions for the delivery of study medicine to participants. Randy

In the study, TD-4208 was generally well tolerated with a similar incidence of adverse events to placebo and there was no significant increase in heart rate or evidence

SyntheMed’s Repel-CV will be marketed throughout Canada by Force3 Medicale, a Montreal-based distributor of cardiac surgery products. The Repel-CV is designed to provide the therapeutic benefit and then

In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral

In this role, Dr Lippman will lead all aspects of the clinical, regulatory and medical affairs functions at Noven. Prior to joining Noven, Dr Lippman served Ethicon, a

Under the agreement, Brookwood has exclusive rights to all pharmaceutical applications of the technology. The PharmaSol technology can be used to formulate drugs into nanostructured lipid carriers (NLCs),